CHM | PHM | |
---|---|---|
Duration of serum/urine β-hCG controls | 1 year | 3–6 months |
Frequency of β-hCG measurement | weekly until 3 × negative, then monthly | weekly until 2–3 × negative, then monthly |
Prophylactic chemotherapy | no | no |
Risk of subsequent GTD | 1–2 % following one previous mole15–18 % following two previous moles | |
Chance for GTN | 15–20 % | 0.5–2 % |